

## **SPECIALTY GUIDELINE MANAGEMENT**

### **ALOXI, EMEND, ANZEMET**

#### **POLICY**

HPHC authorizes medically necessary use of Aloxi®, Emend®, and Anzemet® for treatment of nausea and vomiting when their use (including dosage, frequency, site of administration, and duration of therapy) is reasonable and necessary, clinically appropriate, and supported by evidence-based literature.

**Criteria:** HPHC covers Aloxi® and Emend® for nausea and vomiting related to oncology, post-radiation therapy, pregnancy, post-surgery, and eating disorders when the following criteria are met:

1. Documented use of a moderate or high emetogenic potential IV antineoplastic agent listed in the most recent NCCN Guidelines<sup>1</sup>; OR
2. Prior trial and failure of oral and/or IV Zofran®, Kytril®, or Akynzeo® resulting in nausea, vomiting, or intolerance

HPHC covers Anzemet® for pregnancy-related nausea and vomiting when there is documented failure of oral and/or IV Zofran® or Kytril®.

- ❖ Initial authorizations for ongoing treatment are limited to maximum of 6 months.

For reauthorization for ongoing treatment, clinicians must submit documentation outlining continued need for therapy.

**Exclusions:** HPHC does not cover Aloxi®, Emend®, and Anzemet® for conditions other than those listed in the policy above.

#### **References:**

1. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Antiemesis. Version 1.2015. [http://www.nccn.org/professionals/physician\\_gls/pdf/antiemesis.pdf](http://www.nccn.org/professionals/physician_gls/pdf/antiemesis.pdf)
2. Hesketh, PJ. Prevention and treatment of chemotherapy-induced nausea and vomiting. In: UpToDate, Post, TS (ed), Waltham, MA, 2015.
3. Longstreth, GF. Approach to the adult with nausea and vomiting. In: UpToDate, Post, TS (ed), Waltham, MA, 2015.
4. Di Lorenzo, C. Approach to the infant or child with nausea and vomiting. In: UpToDate, Post, TS (ed), Waltham, MA, 2015.

#### **HPHC Medical Review Criteria**

**Aloxi® Emend® Anzemet®**